中国新药杂志2024,Vol.33Issue(3) :221-228.

人用药品中亚硝胺类杂质的监管现状及思考

Regulatory status and considerations on nitrosamine impurities in human drugs

王功富 汤佳
中国新药杂志2024,Vol.33Issue(3) :221-228.

人用药品中亚硝胺类杂质的监管现状及思考

Regulatory status and considerations on nitrosamine impurities in human drugs

王功富 1汤佳2
扫码查看

作者信息

  • 1. 国家药品监督管理局药品审评中心,北京 100022
  • 2. 国家药品监督管理局药品审评检查大湾区分中心,深圳 518000
  • 折叠

摘要

亚硝胺类杂质是一类具有潜在致突变性的化合物.近年来,多种药品中相继检出亚硝胺类杂质,此类杂质已成为监管机构、制药企业和患者关注的焦点.本文在查阅最新法规指南及相关文献基础上,总结了亚硝胺类杂质的来源、控制、限度及检测方法等方面的研究进展,并提出思考和展望,期望为药品研究和监管工作提供参考.

Abstract

Nitrosamine-type impurities are a class of compounds with potential genotoxicity.In recent years,being detected in many drugs,nitrosamine impurities have become the focus of regulatory authorities and pharmaceutical manufacturers,as well as patients.By reviewing the latest legal guidelines and related literature,this paper summarizes the research progress in the sources,control,limits,and detection methods of nitrosamine impurities,then puts forward considerations and prospects,hoping to provide reference for the research and regulation of drug R&D.

关键词

亚硝胺类杂质/致突变性/监管

Key words

nitrosamine impurities/genotoxicity/regulatory

引用本文复制引用

出版年

2024
中国新药杂志
中国医药科技出版社 中国医药集团总公司 中国药学会

中国新药杂志

CSTPCD北大核心
影响因子:1.039
ISSN:1003-3734
参考文献量8
段落导航相关论文